Evidence map›Paper›PMID 18640140›Full record

ArticleToxicology and applied pharmacology2008

Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure.

Sarah M Mense, Fabrizio Remotti, Ashima Bhan, Bhupendra Singh, Mahmoud El-Tamer, Tom K Hei, Hari K Bhat

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Rat Models of Hormone Receptor-Positive Breast Cancer.Journal of mammary gland biology and neoplasia · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Advances in pharmacological and pharmaceutical sciences · 2022
    Article
  10. Review
  11. Therapeutic Potential of Isoflavones with an Emphasis on Daidzein.Oxidative medicine and cellular longevity · 2021
    Review
  12. Article
  13. Crude Edible Fig (Journal of bioequivalence & bioavailability · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Evidence-based complementary and alternative medicine : eCAM · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sarah M MenseDepartment of Environmental Health Science Mailman School of Public Health Columbia University, New York, NY 10032, USA.
Fabrizio Remotti
Ashima Bhan
Bhupendra Singh
Mahmoud El-Tamer
Tom K Hei
Hari K Bhat
Columbia University · USColumbia University Irving Medical Center · US

Funding

True Metal fac coreP30ES009089 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ami R Zota · 1998 to 2026
$44.7M
Molecular Mechanisms & Importance of Oxidative Stress in Estrogen-Induced CarcinoR01CA109551 · NCI · UNIVERSITY OF MISSOURI KANSAS CITY · PI BHAT, HARI K · 2006 to 2011
$1.1M
NCI NIH HHS CA 109551NCI NIH HHS R01 CA109551NIEHS NIH HHS ES009089NIEHS NIH HHS P30 ES009089
6 · The paper itself

Abstract

Epidemiological evidence indicates that prolonged lifetime exposure to estrogen is associated with elevated breast cancer risk in women. Oxidative stress and estrogen receptor-associated proliferative changes are suggested to play important roles in estrogen-induced breast carcinogenesis. In the present study, we investigated changes in breast morphology and oxidative stress following estrogen exposure. Female ACI rats were treated with 17beta-estradiol (E(2), 3 mg, s.c.) for either 7, 15, 120 or 240 days. Animals were euthanized, tissues were excised, and portions of the tissues were either fixed in 10% buffered formalin or snap-frozen in liquid nitrogen. Paraffin-embedded tissues were examined for histopathologic changes. Proliferative changes appeared in the breast after 7 days of E(2) exposure. Atypical ductal proliferation and significant reduction in stromal fat were observed following 120 days of E(2) exposure. Both in situ and invasive carcinomas were observed in the majority of the mammary glands from rats treated with E(2) for 240 days. Palpable breast tumors were observed in 82% of E(2)-treated rats after 228 days, with the first palpable tumor appearing after 128 days. No morphological changes were observed in the livers, kidneys, lungs or brains of rats treated with E(2) for 240 days compared to controls. Furthermore, 8-isoprostane (8-isoPGF(2alpha)) levels as well as the activities of antioxidant enzymes, such as glutathione peroxidase, superoxide dismutase and catalase, were quantified in the breast tissues of rats treated with E(2) for 7, 15, 120 and 240 days and compared to activity levels in age-matched controls. 8-isoPGF(2alpha) levels displayed time-dependent increases upon E(2) treatment and were significantly higher than control levels at the 15, 120 and 240 day time-points. 8-isoPGF(2alpha) observed in E(2)-induced mammary tumors were significantly higher than levels found in control mammary tissue from age-matched animals. Similarly, alterations in glutathione peroxidase and superoxide dismutase activities were detected in both mammary and tumor tissue from E(2)-treated rats. Taken together, our data reveal that proliferative changes in the breast tissue of ACI rats are associated with increases in 8-isoPGF(2alpha) formation as well as changes in the activities of antioxidant enzymes. These oxidative changes appear to be a function of E(2) exposure and occur prior to tumor development.

Indexed as

Cell ProliferationMammary Glands, AnimalOxidative StressAnimalsCatalaseDinoprostDisease Models, AnimalDrug ImplantsEstradiolFemaleGlutathione PeroxidaseLipid PeroxidationMammary Neoplasms, ExperimentalNeoplasm InvasivenessNeoplasms, Hormone-DependentRats8-epi-prostaglandin F2alphaCatalaseDinoprostDrug ImplantsEstradiolGlutathione PeroxidaseSuperoxide Dismutase

Identifiers

PMID18640140
PMCPMC2593408
OpenAlexW2063355741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.